12,112 Shares in West Pharmaceutical Services, Inc. $WST Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. acquired a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 12,112 shares of the medical instruments supplier’s stock, valued at approximately $4,348,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Empowered Funds LLC increased its holdings in shares of West Pharmaceutical Services by 16.1% during the first quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock worth $361,000 after buying an additional 224 shares in the last quarter. Intech Investment Management LLC boosted its holdings in shares of West Pharmaceutical Services by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after acquiring an additional 1,307 shares in the last quarter. Acadian Asset Management LLC grew its position in West Pharmaceutical Services by 14.1% during the 1st quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock worth $284,000 after acquiring an additional 157 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in West Pharmaceutical Services by 78.2% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after acquiring an additional 197 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in West Pharmaceutical Services by 168.4% in the 2nd quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after purchasing an additional 29,067 shares in the last quarter. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Down 0.2%

Shares of NYSE:WST opened at $352.94 on Friday. The firm has a market cap of $24.84 billion, a P/E ratio of 45.19, a P/E/G ratio of 2.47 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The business has a fifty day simple moving average of $348.61 and a 200 day simple moving average of $299.75. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The company had revenue of $872.30 million during the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $1.84 earnings per share. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Analysts predict that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were issued a dividend of $0.22 per share. The ex-dividend date was Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 11.27%.

Analyst Ratings Changes

Several equities analysts have commented on the company. Wolfe Research started coverage on West Pharmaceutical Services in a research report on Monday, June 1st. They issued an “outperform” rating and a $375.00 target price for the company. Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. Citigroup raised their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. KeyCorp lifted their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, West Pharmaceutical Services presently has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.